EMESIS DURING CHEMOTHERAPY: A REVIEW ON GRANISETRON, ITS EFFICACY AND DELIVERY SYSTEMS
Nausea and vomiting are common problems occurs in disease, non-disease condition and after the chemotherapy, results from the activation of protective physiological mechanism in order to eliminate the toxin from the body. Principal four pathways that act on vomiting center to trigger nausea and vomiting are chemotherapy trigger zone (CTZ), cortex, peripheral pathway and the vestibular system. In emesis different treatment strategy are used in which Granisetron is a drug emerge as a drug of great potential to overcome chemotherapy induce nausea and vomiting. Current review aims to introduce emesis (CIE) during chemotherapy along with different novel therapeutic approaches and various clinical studies. In variety of studies to overcome the CIE novel approaches are of great importance.
2. Aitkenhead AR, Moppett I, Thompson J. Smith and Aitkenhead's Textbook of Anaesthesia: Elsevier Health Sciences; 2013.
3. Biswas B, Rudra A. Comparison of granisetron and granisetron plus dexamethasone for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Acta Anaesthesiol Scand 2003;47:79-83.
4. George E, Hornuss C, Apfel CC. Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting. Curr Opin Anaesthesiol 2010;23:714-21.
5. Morrow GR, Dobkin PL. Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: Prevalence, etiology, and behavioral interventions. Clin Psychol Rev 1988;8:517-56.
6. Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol 2008;9:304.
7. Bell RM. A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nursing 2010;14:365-70.
8. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapyâ€induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-668.
9. Jacobsen PB, Dieâ€Trill M, Holland JC, Andrykowski MA, Redd WH, Hakes TB, et al. Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer. Cancer 1988;61:379-85.
10. Sullivan J, Leyden M, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 1983;309:796.
11. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol 1991;2:107-14.
12. Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian oncology group for clinical research. J Clin Oncol 1987;5:141-9.
13. Cassileth BR, Lusk EJ, Bodenheimer BJ, Farber JM, Jochimsen P, Morrin-Taylor B. Chemotherapeutic toxicity-the relationship between patients' pretreatment expectations and post-treatment results. Am J Clin Oncol 1985;8:419-25.
14. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12:1143-50.
15. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8.
16. Medhus A, Bondi J, Gaustad P, Husebye E. Low-dose intravenous erythromycin: effects on postprandial and fasting motility of the small bowel. Aliment Pharmacol Ther 2000;14:233-40.
17. De Wit R, Aapro M, Blower PR. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? Cancer Chemother Pharmacol 2005;56:231-8.
18. King FD, Jones BJ, Sanger GJ. 5-Hydroxytryptamine-3 receptor antagonists: CRC Press; 1993.
19. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991;254:432-7.
20. Wickham R. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Supportive Oncol 2010;8(2 Suppl 1):10-5.
21. Kast R, Foley K. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5â€HT3 antagonists with good antinausea effects. Eur J Cancer Care 2007;16:351-4.
22. Richman PB, Reischel U, Ostrow A, Irving C, Ritter A, Allegra J, et al. Droperidol for acute migraine headache. Am J Emerg Med 1999;17:398-400.
23. Hentosh P, Peffley DM. The cladribine conundrum: deciphering the drug's mechanism of action. Expert Opin Drug Metab Toxicol 2010;6:75-81.
24. Ashish P, Harsoliya M, Pathan J, Shruti S. A review-Formulation of mouth dissolving tablet. Int J Pharm Clin Sci 2011;1:1-8.
25. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008;26:1261-8.
26. Pahwa R, Piplani M, Sharma PC, Kaushik D, Nanda S. Orally disintegrating tablets-friendly to pediatrics and geriatrics. Arch Appl Sci Res 2010;2:35.
27. Coughlin P, Mavor A. Arterial consequences of recreational drug use. Eur J Vascular Endovascular Surgery 2006;32:389-96.
28. Sharma D, Kumar D, Singh M, Singh G, Rathore M. Fast disintegrating tablets: a new era in novel drug delivery system and new market opportunities. J Drug Delivery Ther 2012;2:74-86.
29. Bhowmik D, Chiranjib B, Krishnakanth P, Chandira RM. Fast dissolving tablet: An overview. J Chem Pharm Res 2009;1:163-77.
30. Jain BV, Patil R, Wankhede S, Patil D, Barhate S. Development of mouth dissolving tablets of granisetron hydrochloride using three different techniques. Int J Pharm Res Dev 2011;3:23-6.
31. Brown D. Orally disintegrating tablets-taste over speed. Drug Delivery Technol 2003;3:58-61.
32. Kaur T, Gill B, Kumar S, Gupta G. Mouth dissolving tablets: a novel approach to drug delivery. Int J Curr Pharm Res 2011;3:1-7.
33. Allen LV, Popovich NG. Ansel's pharmaceutical dosage forms and drug delivery systems: Lippincott Williams and Wilkins Baltimore; 2005.
34. Jass HU, Kohlhepp FU. Effervescent composition. Google Patents; 1974.
35. Rowe R. The cracking of film coatings on filmâ€coated tabletsâ€”a theoretical approach with practical implications. J Pharm Pharmacol 1981;33:423-6.
36. Hede PD, Bach P, Jensen AD. Fluidized-bed coating with sodium sulfate and PVAâˆ’ TiO2, 1. review and agglomeration regime maps. Ind Eng Chem Res 2009;48:1893-904.
37. Tan C, Onsiong M. Pain on injection of propofol. Anaesthesia 1998;53:468-76.
38. Ryoo H-K, Park C-W, Chi S-C, Park E-S. Development of propofol-loaded microemulsion systems for parenteral delivery. Arch Pharm Res 2005;28:1400-4.
39. Nagendrakumar D, Raju S, Shirsand S, Para M. Design of fast dissolving Granisetron HCl tablets using novel co-processed superdisintegrants. J Biosci Tech 2009;1:8-14.
40. Bhagawati S, Hiremath S, Sreenivas S. Comparative evaluation of disintegrants by formulating cefixime dispersible tablets. Indian J Pharm Educ 2005;39:194.
41. Doh HJ, Jung Y, Balakrishnan P, Cho HJ, Kim DD. A novel lipid nanoemulsion system for improved permeation of granisetron. Colloids Surf B 2013;101:475-80.
42. Zheng W-w, Zhao L, Wei Y-m, Ye Y, Xiao S-h. Preparation and the in vitro evaluation of nanoemulsion system for the transdermal delivery of granisetron hydrochloride. Chem Pharm Bull 2010;58:1015-9.
43. PV S, Kinagi M, Biradar S, Gada S, Shilpa H. Formulation design and evaluation of bilayer buccal tablets of granisetron hydrochloride. Ind J Pharm Edu Res. 2011;45:242.
44. Satishbabu B, Srinivasan B. Preparation and evaluation of buccoadhesive films of atenolol. Indian J Pharm Sci 2008;70:175-9.
45. Panzade P, Heda A, Puranik P, Patni M, Mogal V. Enhanced transdermal delivery of granisetron by using iontophoresis. Iranian J Pharm Res. 2012;11:503.
46. Pavan K, Ch P. An approach to determine crystalline content of Granisetron in transdermal patches using X-ray diffraction technique. Int J Drug Delivery 2013;4:492-7.
47. Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Supportive Care Cancer 2011;19:1-4.
48. Fukami Y, Terasaki M, Okamoto Y, Sakaguchi K, Murata T, Ohkubo M, et al. Efficacy of preoperative dexamethasone in patients with laparoscopic cholecystectomy: a prospective randomized double-blind study. J Hepato-Biliary-Pancreatic Surgery 2009;16:367-71.
49. Bhattacharjee DP, Dawn S, Nayak S, Roy PR, Acharya A, Dey R. A comparative study between palonosetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol 2010;26:480.
50. Hwang J, Park H, Lim Y, Do S, Lee S, Jeon Y. Preventing pain on injection of propofol: a comparison between peripheral ketamine pre-treatment and ketamine added to propofol. Anaesth Pain Intensive Care 2009;37:584-7.
51. Siddique R, Hafiz M, Rokeya B, Jamal C, Islam A. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia. Mymensingh Med J. 2011;20:680-8.